A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Study ID

Protocol Number: 19-0642

More information available at ClinicalTrials.gov: NCT03897881

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers